MetaCap

ArriVent BioPharma Inc. (AVBP)

NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

10.52-0.74 (-6.57%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AVBP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$544.13M
EPS (TTM)
-$3.60
52-week range
10.33 – 35.83
Day range
10.38 – 11.35
Volume / Avg
1.05M / 1.37M
Beta
—

52-week range

$10.33$35.83

AVBP stock today

On Nov 20, AVBP ended the session at $10.52, shedding $0.74 (6.57%), versus the S&P 500's 3.70% decline. Shares are 70.6% below their 52-week high of $35.83, set on Jun 26, 2026 and 1.8% above the 52-week low of $10.33, near the bottom of the past year's range. AVBP is down 47.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 48.3%.

ArriVent BioPharma has posted a net loss over the last twelve months (EPS of -$3.60), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ArriVent BioPharma

Company profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Zhengbin Yao Ph.D.
Headquarters
Newtown Square, PA
Employees
77
IPO year
2024

Financial highlights

Full financials

ArriVent BioPharma reported a net loss of $166.3 million, compared with a loss of $80.5 million a year earlier. Diluted earnings per share came in at -$4.32.

ArriVent BioPharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-166.31M$-80.49M$-69.33M
EPS (diluted)$-4.32$-2.56$-32.38

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$26.20+149.05%

  • Strong buy 0
  • Buy 11
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $22.00High $29.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.81 vs $-1.04
Surprise
+22.12%

AVBP news

All AVBP news

ArriVent BioPharma peers

Health Care sector
AVBP peer companies
CompanyPrice% ChgMarket capCompare
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs AVBP
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs AVBP
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs AVBP
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs AVBP
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs AVBP
GERNGeron Corporation0.8707-4.63%$560.94Mvs AVBP
ZVRAZevra Therapeutics Inc.8.76-3.42%$521.26Mvs AVBP
ALMSAlumis Inc.3.96-8.54%$514.09Mvs AVBP

Indexes, lists and sector

ArriVent BioPharma stock FAQ

What is ArriVent BioPharma's stock price today?

AVBP last traded at $10.52 as of Nov 20, 4:00 PM EST, down 6.57% on the day. Prices are delayed at least 15 minutes.

Who is ArriVent BioPharma's CEO?

Dr. Zhengbin Yao Ph.D. is the chief executive officer of ArriVent BioPharma Inc., which has about 77 employees.

What is the AVBP 52-week high?

The 52-week high for AVBP is $35.83 and the 52-week low is $10.33. The stock is currently 70.6% below its high.

Compare AVBP